Global ETD Search

Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.

Results

Showing 1 to 20 of 23 for “"Sandhoff disease"”.

  1. Investigating Sandhoff Disease in Saskatchewan

    Sandhoff disease is an autosomal recessive lysosomal storage disease caused by mutations in the HEXB gene detrimentally affecting the enzyme β-hexosaminidase. A high incidence of Sandhoff disease has been reported in northern Saskatchewan. The variant of the disease present in the province causes …

    regina Repository record for Investigating Sandhoff Disease in Saskatchewan (opens in a new tab) Download PDF for Investigating Sandhoff Disease in Saskatchewan (opens in a new tab)

  2. TUMOR NECROSIS FACTOR ALPHA (TNFα) in SANDHOFF DISEASE PATHOLOGY

    <p><strong>Abstract</strong></p> <p>Sandhoff disease (SD) is a monogenic lysosomal storage disorder caused by a lack of a functional β-subunit of the beta-hexosaminidase A and B enzymes. The clinical phenotype of <em>Hexb</em><sup>-/-</sup>mouse model recapitulates the symptoms and signs of …

    mcmaster Repository record for TUMOR NECROSIS FACTOR ALPHA (TNFα) in SANDHOFF DISEASE PATHOLOGY (opens in a new tab)

  3. THE ENDOPLASMIC RETICULUM STRESS RESPONSE IN THE PROGRESSION OF SANDHOFF DISEASE

    Sandhoff disease (SD), a fatal lysosomal storage disease, results from a deficiency of the β-subunit of the β-hexosaminidase A and B enzymes. This deficiency leads to severe accumulation of GM2 gangliosides in lysosomes within the central nervous system (CNS) resulting in mass neuronal apoptosis. …

    mcmaster Repository record for THE ENDOPLASMIC RETICULUM STRESS RESPONSE IN THE PROGRESSION OF SANDHOFF DISEASE (opens in a new tab)

  4. Enhancement of a novel gene therapy approach for Sandhoff disease through complimentary drug therapy

    … to either the HEXA gene, causing Tay Sachs disease, or a mutation to the HEXB gene, causing Sandhoff disease. The HEXA and HEXB genes are required to produce the α and β subunits of the Hex A enzyme respectively. Using a Sandhoff disease (SD) mouse model (Hexb-/-) we tested the potential of …

    queens Repository record for Enhancement of a novel gene therapy approach for Sandhoff disease through complimentary drug therapy (opens in a new tab)

  5. Lysosomal storage and pathologenesis in a novel in vitro cellular model of Sandhoff disease

    <p>Sandhoff disease is a devastating autosomal recessive GM2 gangliosidosis in which a deficiency of β-hexosaminidase results in lysosomal storage of the enzyme's substrates, including GM2 and GA2 glycolipid as well as glycoprotein-derived oligosaccharides (OS). The effect of individual storage …

    oxford Restricted access

  6. MECHANISMS OF NEURODEGENERATION IN A MOUSE MODEL OF SANDHOFF DISEASE: ROLES OF INFLAMMATION, EXCITOTOXICITY, AND APOPTOSIS

    … disorders are a group of rare neurodegenerative diseases that are collectively common, sharing many aspects with other neurodegenerative disorders, including substrate build-up and neuroinflammation. The GM2 Gangliosidoses, Tay-Sachs disease and Sandhoff disease, are pathologically overlapping …

    mcmaster Repository record for MECHANISMS OF NEURODEGENERATION IN A MOUSE MODEL OF SANDHOFF DISEASE: ROLES OF INFLAMMATION, EXCITOTOXICITY, AND APOPTOSIS (opens in a new tab)

  7. Intrathecal Delivery of a Human Bicistronic Hexosaminidase Vector to Correct Sandhoff Disease in a Murine Model: A Dose-Response Study

    … lysosomal storage disorders including Tay-Sachs disease (TSD), Sandhoff disease (SD), and the AB variant of GM2 gangliosidosis. TSD and SD are characterized by reduced or absent levels of the hydrolase β-hexosaminidase A (Hex A). Normally, the heterodimer Hex A hydrolyzes GM2 ganglioside into …

    queens Repository record for Intrathecal Delivery of a Human Bicistronic Hexosaminidase Vector to Correct Sandhoff Disease in a Murine Model: A Dose-Response Study (opens in a new tab)

  8. Induction of Immune Tolerance to Hexosaminidase M Using Rapamycin and Prednisone in the scAAV9-HEXM Gene Therapy Treatment of Sandhoff Disease

    Sandhoff disease (SD) is a neurodegenerative disorder caused by the toxic accumulation of GM2 gangliosides in the brain. This is due to a deficient enzyme, β-hexosaminidase A (HEXA), involved in the catabolism of GM2 gangliosides. A recently constructed isoenzyme analogous to HEXA, called …

    queens Repository record for Induction of Immune Tolerance to Hexosaminidase M Using Rapamycin and Prednisone in the scAAV9-HEXM Gene Therapy Treatment of Sandhoff Disease (opens in a new tab)

  9. Preclinical Assessment of the scAAV9-HEXM Gene Therapy Vector via a Novel Combined Delivery Method in the Treatment of Sandhoff Disease in a Murine Model

    Sandhoff disease (SD) is a genetic neurodegenerative disorder caused by an excessive accumulation of GM2 gangliosides in neuronal lysosomes. SD arises from a mutation in the HEXB gene which encodes the β-subunit of the enzyme, β-hexosaminidase A, a heterodimer responsible for the hydrolysis of GM2. …

    queens Repository record for Preclinical Assessment of the scAAV9-HEXM Gene Therapy Vector via a Novel Combined Delivery Method in the Treatment of Sandhoff Disease in a Murine Model (opens in a new tab)

  10. Uncovering the Role of Progranulin in Ameliorating Lysosomal Storage Disease

    … modulator, granulin (GRN), and its role in Sandhoff disease. GRN deficiency has been shown to promote neuroinflammation, neuronal death, and leads to a lysosomal storage disorder (LSD) 1-7. Complete loss of GRN causes Batten’s disease (CLN11), which belongs to a class of LSDs1. …

    dominican Repository record for Uncovering the Role of Progranulin in Ameliorating Lysosomal Storage Disease (opens in a new tab)

  11. Elucidating the structure and improving the cellular uptake of HexM, a candidate for enzyme replacement therapy of GM2 gangliosidosis

    Tay-Sachs disease and Sandhoff disease are genetic disorders resulting from mutations in genes HEXA or HEXB, which code for the α- and β-subunits of the heterodimer β-hexosaminidase A (HexA), respectively. HexA is a lysosomal glycosidase responsible for degrading GM2 ganglioside (GM2), a glycolipid …

    manitoba Repository record for Elucidating the structure and improving the cellular uptake of HexM, a candidate for enzyme replacement therapy of GM2 gangliosidosis (opens in a new tab)

  12. Tay-Sachs Disease: Mechanisms of Neuropathology and Potential Therapeutic Strategies Utilizing Human Lysosomal Sialidase

    … Included in this group are Tay-Sachs and Sandhoff disease. Human cases of Tay-Sachs and Sandhoff disease present with devastating neurological deterioration; however, murine models display drastically divergent phenotypes. Tay-Sachs mice avoid pathology via a sialidase-mediated bypass of …

    mcmaster Repository record for Tay-Sachs Disease: Mechanisms of Neuropathology and Potential Therapeutic Strategies Utilizing Human Lysosomal Sialidase (opens in a new tab)

  13. Glycosphingolipid dysregulation and lysosomal dysfunction in motor neuron disease

    … (LSDs) have been studied as discrete metabolic diseases in their own right. However, some links with common late-onset neurodegenerative diseases, including motor neurone disease (MND), have recently emerged. Reports show lipid dysregulation, including increased levels of various …

    oxford Repository record for Glycosphingolipid dysregulation and lysosomal dysfunction in motor neuron disease (opens in a new tab)

  14. Autophagy and Muscle Dysfunction in Lysosomal Storage Diseases

    Lysosomal storage diseases (LSDs) are metabolic diseases which occur as a result of a deficiency of one of the essential lysosomal enzymes, called glycohydrolases. A mutation in the gene encoding one of these enzymes leads to an accumulation of unwanted substrates, resulting in a variety of …

    mcmaster Repository record for Autophagy and Muscle Dysfunction in Lysosomal Storage Diseases (opens in a new tab)

  15. Development of a novel method for β-hexosaminidase A purification and investigation of the transport of an engineered enzyme across the blood-brain barrier

    Tay-Sachs disease (TSD) and Sandhoff disease (SD) are severe autosomal recessive genetic disorders caused by loss-of-function mutations in the HEXA and HEXB genes encoding the heterodimeric enzyme β-hexosaminidase A (HexA). Deficiencies in HexA lead to the pathological accumulation of GM2 …

    manitoba Repository record for Development of a novel method for β-hexosaminidase A purification and investigation of the transport of an engineered enzyme across the blood-brain barrier (opens in a new tab)

  16. Pharmacological approaches for lysosomal storage diseases

    <p>Niemann–Pick disease Type C (NPC) is a neurodegenerative lysosomal storage disorder that arises from defects in lysosomal proteins involved in intracellular lipid trafficking. Cellular pathology leads to clinical neurological manifestations, including ataxia. The anti-vertigo drug …

    oxford Repository record for Pharmacological approaches for lysosomal storage diseases (opens in a new tab)

  17. Long Term Correction of GM2 Gangliosidoses in Sandhoff Mice Through Intravenous Neonatal Gene Therapy, Using a Recombinant Adeno-Associated Viral Vector Expressing a New Hexosaminidase Variant

    … death induces the primary symptoms of the disease; motor and sensory impairments, and seizures. The aim of this study was to observe the long-term in vivo effects of an innovative gene therapy treatment method in a Sandhoff (β-subunit deficient) mouse model. The treatment utilized a new …

    queens Repository record for Long Term Correction of GM2 Gangliosidoses in Sandhoff Mice Through Intravenous Neonatal Gene Therapy, Using a Recombinant Adeno-Associated Viral Vector Expressing a New Hexosaminidase Variant (opens in a new tab)

  18. Development and characterization of GM2 gangliosidoses mouse models

    … in HEXA, encoding the 𝛼-subunit, cause Tay-Sachs disease (TSD) whereas mutations in HEXB, encoding the 𝛽-subunit, cause Sandhoff disease (SD). Successful therapies are available for many lysosomal storage disorders, however none of these are available for treatment of GM2 gangliosidosis. While …

    manitoba Repository record for Development and characterization of GM2 gangliosidoses mouse models (opens in a new tab)

  19. Preclinical Assessment of Intravenous Gene Therapy for GM2 Gangliosidosis

    … in either of these genes lead to Tay Sachs Disease and Sandhoff Disease, respectively, through the disruption of the HexA enzyme. These debilitating diseases are fatal by the age of 4 in the infantile version and have no effective treatment available to patients other than palliative care. …

    queens Repository record for Preclinical Assessment of Intravenous Gene Therapy for GM2 Gangliosidosis (opens in a new tab)

  20. Partial Molecular and Biochemical Characterization of a Sandhoff Mouse Model

    Sandhoff Disease (SD) is a rare genetic disorder which results in progressive neurodegeneration. SD is caused by a build-up of GM2 Gangliosides, a lipid which is stored in the lysosome of neurons. It can occur in infantile, juvenile and adult forms; in the severe, infantile form, death occurs by …

    queens Repository record for Partial Molecular and Biochemical Characterization of a Sandhoff Mouse Model (opens in a new tab)

Page 1 of 2